News

Onxeo announces evolution in the Board of Directors — Onxeo offentliggør ændring i bestyrelsen

Mr. Patrick Langlois is planning to step down from the chairmanship in early 2016 for personal reasons Mr. Joseph Zakrzewski is joining the Board and is expected to be appointed Non-Executive Chairman in 2016 Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative biopharmaceutical company specializing in the development of orphan oncology drugs, today announced…read more →

Onxeo announces positive DSMB recommendation for continuation of Livatag® ReLive study in HCC — Onxeo offentliggør positiv anbefaling fra DSMB om at fortsætte ReLive-studiet med Livatag® mod leverkræft

Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today announced that it has received a unanimous recommendation from the Data Safety Monitoring Board (DSMB), the independent European board of experts that monitors the safety of the Livatag® Phase III trial, “ReLive”, to continue the study…read more →

Publication of a new letter to shareholders — Offentliggørelse af nyt aktionærbrev

Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today announces the publication of its new letter to shareholders. This issue is devoted to our orphan oncology product Beleodaq®. You will find full information about the product, its key features and indications, as well as interviews…read more →

Decision in the litigation opposing Onxeo to the companies Eurofins and ABL – Afgørelse i retssagen mod Eurofins og ABL

Decision in the litigation opposing Onxeo to the companies Eurofins and ABL Recognition of  Eurofins’s debt to Onxeo resulting from the absence of payment of the option This debt is compensated by damages benefiting Eurofins None of the parties obliged to the payment of has to pay an indemnity towards the other Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an…read more →

Corporate Governance prize awarded by AGEFI: Onxeo receives “Silver Governance” for the second consecutive year

Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative biopharmaceutical company specialized in the development of orphan oncology drugs, has been awarded for the second consecutive year the “Silver Governance” in the small and midcap companies category at the Twelfth Annual Corporate Governance Awards held by the French financial magazine AGEFI on September 16, 2015. The Corporate Governance Prizes reward…read more →

Onxeo files application for key Livatag® patent — Onxeo indleverer ansøgning om vigtigt patent for Livatag®

Potential expansion of Livatag IP estate to extend commercial exclusivity through 2036 Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative biopharmaceutical company specialized in the development of drugs for orphan oncology diseases, today announced that it has filed an international patent application to protect the overall compound related to its primary liver cancer orphan oncology product Livatag®. The patent…read more →

Onxeo to present at InvestorDagen 2015 – Onxeo repræsenteret ved InvestorDagen 2015

Onxeo to present at InvestorDagen 2015 The largest Danish private investor event September 22, 2015, Radisson Blu Scandinavia Hotel, Copenhagen Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative biopharmaceutical company specialized in the development of drugs for orphan oncology diseases, will be presenting at InvestorDagen 2015, which will be held in Copenhagen, Denmark on September 22, 2015 at the…read more →

Publication of a Shareholders Letter – Offentliggørelse af nyhedsbrev til aktionærerne

Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today announces the publication of a Shareholders Letter (1). This Shareholders Letter updates on major achievements of the first half of 2015 and on the company’s short and middle term catalysts. (1)    The Shareholders Letter is available on the website at: www.onxeo.com…read more →

Onxeo Reports First Half 2015 Business Update and Consolidated Accounts – Onxeo informerer om sine forretningsmæssige tiltag og resultatet for 1. halvår 2015

Livatag® Phase III trial in HCC: 50% of patients randomized Scientific recognition of Validive® and Beleodaq® preclinical and clinical data at ASCO Annual  Meeting and MASCC/ISOO International Symposium Sound financial position with €42.9 million cash  Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today reported its consolidated half-year accounts as…read more →

Update on ReLive, Livatag® international phase III clinical trial in HCC – 50% patients randomized – Opdatering om ReLive, det internationale kliniske fase III-studie med Livatag® til behandling af leverkræft 50% patienter randomiseret

Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, updates on the clinical development status of ReLive , the Livatag® phase III trial  in the treatment of hepatocellular carcinoma. Livatag®, a new therapeutic approach for hepatocellular carcinoma Livatag® is based on the innovative « Transdrug ™ » technology  designed to formulate a chemotherapy (doxorubicin)…read more →

Meetings with the financial community during the 2nd semester of 2015 – Møder med finansverdenen i 2. halvår 2015

Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, announces its meetings with the investors and shareholders during the second semester 2015. September 16, 2015 11:30am: – Analyst and Investor Meeting 5:30pm: Audio/web conference September 22, 2015 InvestorDagen Radisson Blu Scandinavia Hotel – Copenhagen, Denmark October 7 & 8, 2015 European…read more →

Validive® at the MASCC/ISOO International Symposium: Oral presentation of Phase II trial results and meeting with its International Advisory Board – Data om Validive® på MASCC/ISOO International Symposium: Mundtlig præsentation af resultater fra fase II-studiet og møde med det internationale ekspertudvalg

Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, has presented Validive® (clonidine Lauriad®) Phase II clinical trial results at the MASCC/ISOO International Symposium which took place in Copenhagen from June 25 to June 27, 2015 and on this occasion, held a meeting of its Advisory Board to discuss  design of…read more →

Beleodaq® (belinostat) pivotal BELIEF study results published in the Journal of Clinical Oncology (JCO) – Resultater fra det pivotale BELIEF-studie med Beleodaq® (belinostat) publiceret i Journal of Clinical Oncology (JCO)

Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today announced the publication of results from the pivotal BELIEF (PXD101-CLN-19) study which was selected as a Rapid Communication in the Journal of Clinical Oncology (JCO), the journal of the American Society of Clinical Oncology.  The JCO is peer-reviewed and is one…read more →

Onxeo consolidates its industrial property with a US patent protecting Validive® until 2029 – Onxeo styrker sine immaterielle rettigheder med et amerikansk patent til beskyttelse af Validive® frem til 2029

Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today announced the allowance by the US Patent and Trademark  Office (USPTO) of a patent covering its product Validive® until September 2029. Validive® is based on Onxeo’s mucoadhesive technology Lauriad® and has obtained positive Phase II results last year in the prevention…read more →